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Abstract
Introduction: To the best of our knowledge, this case report describes the longest disease-free
interval between primary diagnosis and metastatic recurrence of an osteosarcoma.
Case presentation: A 35-year-old Caucasian American man presented with asymptomatic lung
metastases 21 years after being diagnosed and treated for lower extremity osteosarcoma. He
underwent curative lung resection, but 2 years thereafter developed metastatic disease in the
scapula and tibia and, after resection and chemotherapy, is in remission 1 year later.
Conclusion:  This case highlights the importance of long follow-up periods and continued
surveillance of osteosarcoma patients after initial curative treatment.
Introduction
Osteosarcoma is the third most common cancer in adoles-
cence, after lymphomas and brain tumors. One-third of
patients who present with osteosarcoma will have recur-
rent disease. Within the recurrent disease group, 95% of
relapses occur within the first 5 years, with the lung as the
most common site of metastases. Reported relapses
beyond 10 years are rare in the literature. We describe the
case of a 35-year-old man who presented with lung metas-
tasis 21 years after undergoing surgical resection and adju-
vant chemotherapy for osteosarcoma of the femur. The
patient underwent a curative resection. Histological stud-
ies described this calcified lesion as osteosarcoma, thereby
confirming, to the best of our knowledge, the longest
known disease-free interval to metastatic recurrence
reported in the English literature. We discuss the relevant
clinical knowledge regarding late relapse of osteosarcoma.
Case presentation
At the age of 14, the patient was diagnosed with osteosar-
coma of the left femur. He received neoadjuvant chemo-
therapy consisting of doxorubicin and cisplatin, and
underwent above-the-knee amputation of his left leg.
Adjuvant chemotherapy included doxorubicin, meth-
otrexate and vincristine.
Twenty-one years after his initial osteosarcoma resection,
the patient presented with cellulitis of his left thigh, which
was treated successfully. During his hospital stay, a chest
X-ray revealed a mass in the infrahilar area of the patient's
right thorax (Figure 1). A computerized tomography (CT)
scan described this 5 × 4 × 5 cm mass as considerably cal-
cified with a Hounsfield unit density measurement iden-
tical to that of the patient's bone (Figure 2). There was no
evidence of recurrence at the primary site and further met-
astatic work-up was negative.
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The patient underwent curative resection, and pathology
of the right middle and lower lung lobes revealed osteosa-
rcoma with extensive chondroblastic differentiation (Fig-
ure 3a and 3b). This was consistent with the histologic
description of the primary cancer. The patient was dis-
charged within one week postoperatively and was well for
two years postoperatively without signs of recurrence.
Subsequently, the patient underwent surgical resection of
the right tibia and partial resection of the left scapula for
metastatic disease, after which he completed additional
chemotherapy and is currently doing well three years after
his lung surgery.
Discussion
Osteosarcoma is the most common primary malignancy
of the bone, with a peak incidence in the second decade
and an additional peak of incidence in elderly individuals
[1]. Historically, prognosis was abysmal, and although the
addition of aggressive chemotherapeutic regiments to sur-
gical excision has improved long-term survival, 30% to
40% of patients develop metastases [2], with the lung as
the most common metastatic location [1,3-6]. It has been
suggested that the addition of aggressive chemotherapy
has altered the incidence, location and timing of metasta-
sis [5]. Almost one-third of patients with osteosarcoma
will experience recurrence of the disease. In these patients,
95% of relapses will occur within 5 years of the initial
diagnosis, with an average time to relapse of 1.6 years
[1,7]. The lung is the most common site of metastasis,
with 77% to 92% of patients experiencing recurrence at
this site [5], and an average survival after recurrence of less
than 1 year [7]. Patients in a second remission have a 70%
to 80% chance of second relapse within 1 year [6].
Late recurrence is usually described as occurring more
than 5 years after primary osteosarcoma treatment. How-
ever, the recorded cases with the longest time spans before
recurrence are all of local recurrence, such as the report by
Lau et al., which describes local recurrence 20 years after
surgery [8]. The Rizzoli Institute study examined 648
patients from 1983 to 1997, with the longest local recur-
rence at 19.3 years. The longest time interval reported of
metastatic recurrence in the Rizzoli study was 11.4 years.
The Cooperative Osteosarcoma Study (COSS), in an anal-
ysis of 1,702 osteosarcoma patients treated between 1980
to 1998, described the longest time interval before recur-
rence at 14.3 years [8].
In 2004, Strauss and colleagues published an article
describing eight patients seen at the London Bone and
Soft tissue Tumor Service who had relapsed after long dis-
ease-free intervals [5]. The article also reviewed seven
major studies on late relapse, defined as recurrence greater
than 5 years after initial diagnosis, in patients treated for
localized osteosarcoma. These seven studies included lit-
erature over a total of 23 years from Memorial Sloan Ket-
tering, the Cooperative Osteosarcoma Study (COSS-86)
analysis, three separate studies from the Rizzoli Institute,
the Cooperative Osteosarcoma Study (COSS) intergroup
analysis and Strauss' examination of 484 patients in Lon-
don. Late relapse, defined as recurrence greater than 5
Transaxial chest computed tomography scan demonstrating a  calcified tumor in the right middle lobe adjacent to the  oblique fissure Figure 2
Transaxial chest computed tomography scan demon-
strating a calcified tumor in the right middle lobe 
adjacent to the oblique fissure.
Chest X-ray showing a right infrahilar tumor Figure 1
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years after initial diagnosis, occurred in 57 out of 2,924
patients, an incidence of 1.9%. The longest disease-free
interval to recurrence was the one previously mentioned
from the COSS study at 14.3 years after treatment.
The most recent study on late recurrence comes from the
Rizzoli Institute in 2006 and included 648 patients with
non-metastatic osteosarcoma to determine predictive fac-
tors for late recurrence [4]. Twenty-four out of the 648
patients had late recurrent disease, and 20 out of the 24
patients who recurred had pulmonary metastases. The
longest disease-free interval to metastatic recurrence was
11.4 years.
Conclusion
Our patient was initially treated for osteosarcoma with
surgical resection and chemotherapy, and presented 21
years later with a single metastasis to the right lung. Oste-
osarcomas are the least likely bone tumors to relapse late,
making this case even more unusual. This case represents
the longest disease-free interval to metastatic recurrence in
the English literature, and underscores the need for con-
tinued surveillance of osteosarcoma patients.
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A - Bony matrix predominates the lung mass with atypical cells trapped within Figure 3
A - Bony matrix predominates the lung mass with atypical cells trapped within. Hemotoxylin and Eosin; original 
magnification 50×. B - Irregular hyperchromatic spindle cells within lesional matrix. Hematoxylin and Eosin; original magnifica-
tion 125×.
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